Klubabend mit Norbert Bischofberger (Gilead) und Josef Penninger (IMBA)

Klubabend mit Norbert Bischofberger (Gilead) und Josef Penninger (IMBA)
Dienstag, 9. Februar, 18.00 Uhr
Presseclub Concordia, Bahnkasse 8 (1010 Wien)

„Going public“

„Going public“ is an ambiguous term. It can mean seeking the attention of a lay audience in order to raise the awareness and attention for science in general and basic research in particular. It can also mean selling shares that were formerly privately held to new investors for the first time, otherwise known as an initial public offering (IPO).

The two scientists Norbert Bischofberger and Josef Penninger know a lot about going public in every sense of the word. At the Klubabend on Tuesday, February 9, 2016, 6 pm, they will discuss with Oliver Lehmann, the chairman of the Austrian Association of Science and Education Journalists, the advantages and the pitfalls of the interaction between science and society, research and business.

How do scientists perceive the role of journalists? What are their expectations? How well should journalists be informed before contacting a scientist? What can journalism contribute to the dissemination of science? What does the disruption of the classic publication model in favor of open access mean for the dissemination of science? How should scientists and journalists handle the diminishing function of the traditional bottleneck of science journals?

The „Chatham House Rule“ applies: „When a meeting, or part thereof, is held under the Chatham House Rule, participants are free to use the information received, but neither the identity nor the affiliation of the speaker(s), nor that of any other participant, may be revealed“.

The Klubabend will be held (or at least start) in German and English with German questions and English answers.

Light refreshments will be served afterwards.

Dr. Norbert Bischofberger, Executive Vice President, Research and Development and Chief Scientific Officer at Gilead; located in Foster City (Kalifornien), with 7.500 employees and a turnover of $ 24.5 bn one of the largest biopharmaceutical companies worldwide (NASDAQ: GILD).

Dr. Josef Penninger, Scientific Director of IMBA, Wittgenstein-Laureate 2014

Dieser Beitrag wurde unter Eigenveranstaltungen, News, Veranstaltungen veröffentlicht. Setze ein Lesezeichen auf den Permalink.

Schreibe einen Kommentar

Deine E-Mail-Adresse wird nicht veröffentlicht. Erforderliche Felder sind mit * markiert.